Following on from information provided to NICE by the company in August 2019, the appraisal of Melanoma (metastatic, BRAF wild-type, untreated) - atezolizumab (with cobimetinib) [ID1470] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1470 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 16 November 2022 | Discontinued. Following on from information provided to NICE by the company in August 2019, the appraisal of Melanoma (metastatic, BRAF wild-type, untreated) - atezolizumab (with cobimetinib) [ID1470] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 08 August 2019 | Suspended. The company have informed NICE that IMspire170, a phase 3 trial of cobimetinib plus atezolizumab for untreated BRAF V600 wild-type advanced melanoma, [ID1470] did not meet its primary endpoint of progression free survival by independent review and therefore the company will not be filing for a Marketing Authorisation Application to the European Medicines Authority in this indication at this time. Therefore NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred, NICE will continue to monitor any development and will update interested parties if the situation changes. |
| 17 October 2018 | In progress. Topic referred |
For further information on our processes and methods, please see our CHTE processes and methods manual